JTC PLC/ JE00BF4X3P53 /
2024-11-12 5:21:11 PM | Chg. -18.00 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
973.00GBX | -1.82% | 3,216 Turnover(GBP): 31,425.8400 |
-Bid Size: - | -Ask Size: - | 989.00 | 971.00 |
GlobeNewswire
08-27
Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
08-27
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
08-21
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual...
GlobeNewswire
08-20
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Amp...
GlobeNewswire
08-19
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiat...
GlobeNewswire
08-16
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08-14
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corpora...
GlobeNewswire
08-14
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08-14
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire
08-13
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Confere...
GlobeNewswire
08-13
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-13
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near...
GlobeNewswire
08-12
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
GlobeNewswire
08-08
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
GlobeNewswire
08-07
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2...
GlobeNewswire
08-02
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment